With just over half of the expected vote total counted, it’s too early to tell whether California voters will approve [...] …
Blog Posts
Arkansas state officials and providers are urging the U.S. Supreme Court not to take up a drug industry trade group’s [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The U.S. Supreme Court heard arguments Tuesday on a case challenging a federal rule over disproportionate share hospital (DSH) calculations [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A New Era for Value-Based Care: Driving Better Outcomes Through Innovation and Patient-Centered Care
SPONSORED CONTENT
In 2021, the Centers for Medicare & Medicaid Services (CMS) Innovation Center set a bold new strategy for healthcare delivery which aims to have all or the majority of patients in
…
When voters across the U.S. cast their ballots in Tuesday’s elections, they will not just be deciding who will control [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A major group purchasing organization (GPO) is suing the federal government over a policy that it claims unlawfully restricts how [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
The 340B program continues to be a central topic of discussion in the pharmaceutical landscape, especially as specialty medications become an increasing portion of healthcare spending. Specialty pharmacies, covered entities (CEs), and manufacturers are navigating a complex environment shaped by regulatory updates, financial
…
Eli Lilly is backing Sanofi’s lawsuit to compel the federal government to release all 340B contract pharmacy agreements, arguing that [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drugmaker Boehringer Ingelheim (BI) will begin requiring all 340B covered entities to submit claims data to continue accessing 340B drugs [...] …